Each year, millions of injections are administered to damaged joints, temporarily masking pain. These treatments manage symptoms without healing the underlying defect, and for many patients, end the same way: a metal implant and long recovery.

We started EpiBone because the nearly 600+ million people living with osteoarthritis (OA) worldwide deserve a better answer than a lifetime of injections and a countdown to surgery. OA is the number one cause of disability in both civilian and military populations. The $4B U.S. osteoarthritis injection market exists entirely to ease pain that no current treatment can resolve.

EpiBone is building something fundamentally different. Drawing on decades of research from Columbia University and MIT's Langer Lab, our team developed a way to grow living bone and cartilage from adult stem cells. We carefully mature stem cells in our proprietary bioreactor to replicate the architecture, mechanics, and biology of native tissue. The result is more than a synthetic substitute or a temporary fix: EpiBone generates living tissue that remodels, adapts and integrates as the patient lives their life.

Six patients have already been implanted in our bone trial. Since implantation, zero product-related adverse events have been detected. We are the first and only company with FDA Investigational New Drug (IND) clearances for both stem cell-based bone and cartilage products. IND clearances are the government authorization required to begin safe testing in humans.

This round offers patients, medical professionals, advocates, and believers in regenerative medicine the opportunity to invest in what we believe will become the new standard of care, joining an investor base that includes Tier 1 venture capital firms and major health systems.

EpiBone is clinical-stage technology built with real human data.

Twelve years ago, our founders left Columbia University with a question no one had answered: what if you could grow a patient's own bone and cartilage in a lab, and give it back to them?

Fast forward to August 2023 when we completed our Phase I/IIa bone trial. Every patient who has been treated is in active follow-up today, with zero product-related adverse events detected. Twelve years of tissue engineering science, cGMP manufacturing, and a deliberate regulatory strategy earned us FDA IND clearances for both stem cell based bone and cartilage products - a position no other company holds.

Our treatments are designed to meet the highest regulatory standards. The FDA Investigational New Drug clearances we hold for our products were earned through peer-reviewed science, pharmaceutical-grade manufacturing, and years of trusted and transparent engagement with regulators.

The U.S. Air Force's AFWERX program selected us for $2.5M in non-dilutive contracts, funding the next phase of product development and clinical expansion alongside our existing investor base.

Spun out of Columbia and MIT's Langer Lab, our advisors include Robert Langer, the most cited engineer in history and co-founder of Moderna, and Henry Kravis, founder of KKR and former Chairman of Columbia Business School. We've now raised $50M+ from nearly 200 investors, with $1.1M in 2026 revenue projected entirely from non-dilutive government sources.

Today, 32.5 million Americans live with osteoarthritis — a number projected to reach 67 million by 2030. Globally, 595 million people are affected, or 1 in 13 people alive today. Patients are typically offered three solutions: corticosteroids which reduce inflammation and temporarily relieve pain; hyaluronic acid, which lubricates but doesn't repair; and platelet-rich plasma, which has high variability in outcomes.

Cartilage doesn't heal on its own. Once it's gone, it's gone. Not one product on the market regenerates tissue. When injections stop working, the answer is often a metal implant with a 10–20 year lifespan. Then another surgery.

Meanwhile, a parallel $10B industry of stem cell clinics is surging, projected to hit $236B over the next decade. Across 2,750 U.S. clinics, patients desperate for relief pay tens of thousands of dollars for a wide range of treatments with varied results. EpiBone is the answer to that demand.

EpiBone grows living bone and cartilage from adult stem cells. We deliver pre-grown, functional tissues that are ready to integrate with the patient's own biology from day one.

For our bone product, a surgeon takes a CT scan and a small fat biopsy. We isolate the patient's own stem cells, seed them onto an anatomically shaped scaffold inside our proprietary bioreactor, and deliver controlled nutrients, oxygen, and mechanical loading to mature the cells into functional bone tissue over three to four weeks.

For our cartilage products, we draw from a banked adult cell supply, eliminating the need for a patient biopsy entirely. Same bioreactor process and same maturation principles, but faster to deploy and available off the shelf, as compared to the bone product.

The graft arrives alive, ready to integrate into the patient's existing tissue, remodeling and adapting as they live their life.

Our platform powers four products in active development:

Three things make EpiBone unparalleled.

EpiBone is the first and only company to hold FDA Investigational New Drug clearances for both stem cell-based bone and cartilage products. No other company holds this position, and we spent 12 years building it.

Sarindr Bhumiratana is the lead inventor of 11+ patent families spanning our bioreactor systems, cell processing techniques, and tissue maturation protocols, with peer-reviewed science published in PNAS, Science Translational Medicine, and the American Journal of Sports Medicine. Active filings cover the U.S., EU, UK, Germany, France, Korea, Japan, Australia, and Canada. The portfolio reflects twenty years of iteration, publication, and protection.

Florida's Right-to-Try statute (FL SB 1768, effective July 2025) creates a patient access pathway that runs in parallel with our FDA submission track. Each treatment provides real-world safety data that advances our regulatory roadmap. We reach patients sooner, build the evidence base, and move toward full approval, with each step reinforcing the next.

EpiBone has been featured in Bloomberg, CNN, CNBC, Forbes, and Fast Company, and named a World Economic Forum Technology Pioneer. In 2026, Fast Company ranked EpiBone #6 among the Most Innovative Small Companies in the world. CEO Nina Tandon was named one of Fast Company's 100 Most Creative People in Business and serves as a Board Member of Emerging Companies for the Biotechnology Innovation Organization (BIO).

The surgeons who implanted our grafts stated it plainly:

EpiBone was built by scientists who spent a decade doing the work before anyone was watching.

Nina Tandon started as a Fulbright Scholar, trained as an electrical engineer at Cooper Union and MIT, earned her PhD and MBA from Columbia, then went on to McKinsey before co-founding EpiBone. She has led the company through 12 years, $50M+ in fundraising, and the first-ever human bone tissue engineering clinical trial.

Sarindr Bhumiratana is the principal inventor and has been building this technology since his PhD at Columbia in 2012. He runs R&D, engineering, quality, manufacturing, and clinical operations simultaneously.

EpiBone’s advisory bench reflects the credibility of the science. Robert Langer, godfather of tissue engineering, sits on the board. Henry Kravis advises on business strategy, and Dr. Brian Cole, NBA Team Physician of the Year, is a clinical advisor.

Investors include Cedars-Sinai, Alexandria Venture Investments, Kendall Capital Partners, Hackensack Meridian Health (Bear's Den), Muang Thai Life Insurance.

The U.S. osteoarthritis injection market is $4 billion, and not one of those injections regenerates tissue. The space is massive, underserved, and overdue for a product that actually works.

The market for stem cell treatments, which is characterized as unregulated and generic, has doubled since 2016. It’s projected to grow from $10B to $236B over the next decade, 90% of it operating outside regulatory oversight. EpiBone will meet that demand with rigorous science, conscientiously collected human clinical data, and a regulatory track record built over 12 years.

Beyond the osteoarthritis entry point, we are defining a category with EpiBone's four-product platform addressing craniofacial reconstruction, cartilage repair, osteoarthritis, and osteoporosis, each also a substantial market in its own right.

Each channel also reduces the cost of the next one. Military contracts pay us to advance the pipeline today. Right-to-Try expands patient access and generates live safety data that accelerates our FDA submission. International partnerships produce clinical evidence and milestone payments simultaneously including $1.75M secured for the UAE osteoporosis trial. The result is a development strategy that expands access and is self-funded as it advances.

We've spent 12 years building the foundation. Now we’re building on top of it.

Regenerative medicine has produced some significant outcomes in modern biotech. Genzyme was acquired by Sanofi for $20.1B. MACI, the only FDA-approved cartilage repair product, is now Vericel's flagship, driving hundreds of millions in annual revenue. The tissue engineering exit playbook exists, and the acquirers are well-capitalized: Zimmer Biomet, Stryker, DePuy Synthes, Smith & Nephew, and sovereign wealth funds like ADQ.

EpiBone's near-term plan is to close this round, pre-launch in Florida and internationally, and raise a $30M Series B within 12 months (not guaranteed) to fund full FDA approval and national reimbursed launch. Our model projects profitability in 2029 and $259M in revenue by 2030, across four products and three commercial channels.

Regenerative medicine has already produced landmark exits, and strategic acquirers like Zimmer Biomet, Stryker, and sovereign wealth funds are active today. Whether our outcome is acquisition, licensing, or a public offering, the value we're building is the same: a regulated, IP-protected, clinically validated platform, in a market that has no dominant player.

Forward-looking projections are not guaranteed.

EpiBone has spent 12 years building an unparalleled commercial pipeline. We have the human data, the military contracts, and a regulatory pathway to bring living tissue to market. What we're building with this round is the community of patients, advocates, athletes, and believers who will be part of the story getting us there.

Every investment signals patient demand and increases access for those living with the daily challenge of osteoarthritis and lost mobility.

Here's to the future of living medicine.